Amgen (AMGN): 12% Beat, 4% Real Growth, Debt Up $2.7B. Is AMGN Stock a Buy?

Amgen Inc. (AMGN) Q2 2026 — Reported August 4, 2026 AFTER the US close, for the calendar quarter ended June 30, 2026. Total revenue $10,054M, +10% YoY vs ~$9,426M expected. Non-GAAP diluted EPS $6.29 vs $5.62 expected - an 11.9% beat - but only +4% against $6.02 a year ago. GAAP diluted EPS $4.37, up 65% from $2.65. Free cash flow $3,489M vs $1,911M. FY2026 guidance RAISED for the second time: revenue $38.2-39.4B (from $37.1-38.5B) and non-GAAP EPS $22.30-23.50 (from $21.70-23.10). AMGN closed the regular session at $390.02, up 2.94% into the print, 1% below its record close of $393.10 on July 28. Amgen beat by 11.9% and raised full-year guidance twice - and underneath it, non-GAAP EPS grew just 4%, because consensus had modelled a 7% DECLINE from last year's $6.02. Non-GAAP operating margin FELL half a point to 48.4% on revenue up 10%. The guidance raise was smaller than the beat: Amgen beat by $0.67 and lifted the full-year midpoint by $0.50, so with H1 at $11.44 the guide implies $11.46 in H2 - dead flat on rising revenue. Meanwhile debt outstanding went UP $2.7B in six months, to $57.3B from $54.6B at the year end, and there were ZERO share repurchases in the quarter against $1.4B of dividends. And the denosumab cliff arrived: Prolia -32% and XGEVA -34%, together $1,111M against $1,654M a year ago - $543M gone in one quarter, a $2.2B annual run-rate hole - while Enbrel's net selling price fell 22% under IRA Medicare Part D price setting. THE CALL: HOLD (3/5, A GOOD QUARTER, ALREADY IN THE PRICE) — base-case value ~$356.0 vs ~$390.02 today. KEY METRICS: - CALL: HOLD 3/5. Fair value ~$356 against a $390.02 close - about 9% of downside. This is NOT a call against Amgen; the quarter was good and the portfolio transition is working. It is a call against paying a record price for 4% earnings growth. Method: a ten-year levered free-cash-flow DCF. H1 free cash flow was $4,966M ($6,191M operating cash flow less $1,225M capex); we carry FY2026 at ~$10.5B, growing 5% for five years then 3% for five, 2% terminal, discounted at an 8.5% cost of equity. Because this cash flow is measured AFTER interest, the result is already equity value - no net debt subtracted, or you double count. PV of ten years $85.9B plus discounted terminal value $107.8B = $193.7B over 544M diluted shares = $356. Grid at 7.5/8.5/9.5%: bear $330/$279/$243, base $423/$356/$307, bull $540/$453/$388. A 25/55/20 weighting also gives $356. Note honestly: FOUR of those nine cells sit ABOVE the price. This is a fair-value call, not a bubble call. - REVERSE DCF - WHAT $390.02 REQUIRES: 544M diluted shares x $390.02 = $212.2B of equity. Holding everything else, that needs free cash flow compounding at about 6.5% a year for five years instead of 5% - against the 4% non-GAAP EPS growth Amgen just delivered and the 4.8% its own FY2026 guidance implies (midpoint $22.90 vs $21.85 in 2025). Or, holding our growth, it needs a cost of equity of 7.95% for a company carrying $43.3B of net debt into a denosumab cliff. On enterprise value ($212.2B equity + $43.3B net debt = $255.5B) the stock trades at 24.3x our FY2026E free cash flow, a 4.95% free cash flow yield, 17.0x forward non-GAAP EPS and 23.7x GAAP EPS - the non-GAAP figure adds back roughly $6.08 a share of acquisition amortisation. - THE BEAT IS AGAINST A FALLING BAR: $6.29 vs $5.62 is an 11.9% beat, but Amgen earned $6.02 in the same quarter last year, so consensus had modelled a 7% DECLINE. Real growth was 4%. Revenue grew 10% ($10,054M vs $9,179M) while non-GAAP operating income grew only 7% ($4,612M vs $4,293M) and the non-GAAP operating margin FELL 0.5 points to 48.4%. The non-GAAP tax rate rose from 14.2% to 15.6%. GAAP operating income was $3,514M (36.8% of product sales, +6.5 points) and GAAP net income $2,375M. Product sales were $9,537M, +9%, all of it volume. - THE GUIDANCE RAISE IS SMALLER THAN THE BEAT: FY2026 non-GAAP EPS guidance went $21.60-23.00 (February) to $21.70-23.10 (April) to $22.30-23.50 now - a midpoint of $22.40 to $22.90, up $0.50 after a $0.67 beat. H1 non-GAAP EPS was $11.44, so the full-year midpoint implies $11.46 in H2: dead flat, on revenue guided a full $1.0B higher at the midpoint ($37.8B to $38.8B). Management is signalling continued margin compression, and the MariTide Phase 3 programme is the reason. Capex guided ~$2.6B; buybacks capped at $3.0B with none used yet. - THE DENOSUMAB CLIFF IS HERE: Prolia $759M, DOWN 32% (volume -20%, net price -12%) and XGEVA $352M, DOWN 34% (volume -22%, price -8%) - same molecule, denosumab, with biosimilars launched globally and, in Amgen's words, more expected. Together $1,111M vs $1,654M = $543M lost in one quarter, a $2.2B annual run-rate hole. Add Otezla $491M (-21%), Enbrel $580M (-4% but net selling price -22% from IRA Medicare Part D price setting effective Jan 1, plus 340B mix), KYPROLIS $314M (-17%) and MVASI $153M (-20%): about $2.65B of quarterly sales versus $3.45B a year ago, down 23%. That is roughly a quarter of product sales in structural decline. - AND YET IT GREW 10%, BECAUSE THE NEW PORTFOLIO IS WINNING: the six key growth drivers grew 26% and are nearly 70% of product sales; 22 products grew double digits and 17 annualise above $1B. Repatha $953M (+37%), EVENITY $714M (+38%), TEZSPIRE $486M (+42%), UPLIZNA $335M (+90%), IMDELLTRA/IMDYLLTRA $288M (+115%), PAVBLU $287M (+121%), BLINCYTO $472M (+23%), TEPEZZA $576M (+14%), KRYSTEXXA $400M (+15%), Nplate $430M (+17%), TAVNEOS $150M (+36%), Vectibix $338M (+11%), LUMAKRAS $111M (+23%), AMJEVITA $155M (+17%). - THE BALANCE SHEET NOBODY CHECKED: debt outstanding was $57.3B at June 30 ($5,445M current + $51,859M long-term), UP $2.7B from $54.6B at December 31 - after falling from $60.1B at the end of 2024. Cash rose to $14.0B from $9.1B, so net debt fell only about $2.2B, to $43.3B - roughly 4.1x our FY2026E free cash flow. Total shareholders' equity is $11,688M on $95,639M of assets, a 12% equity ratio. Dividends paid $1.4B at $2.52 a share (+6%); share repurchases in the quarter: NONE. The dividend alone consumes about 52% of estimated FY2026 free cash flow. FY2025 free cash flow was $8.1B, DOWN from $10.4B in 2024. - MARITIDE IS THE WHOLE OPTION: MariTide (maridebart cafraglutide) activates GLP-1 and antagonises GIPR, pitched on dosing - monthly to start and as few as 4 or 6 doses a year to stay on. Running now: MARITIME-1 and -2 in weight management, MARITIME-CV, MARITIME-HF, MARITIME-OSA-1, MARITIME-SWITCH (off weekly tirzepatide or semaglutide), plus two long-term extensions; three more Phase 3s in type 2 diabetes start in 2026 and a Phase 2b in liver fat is enrolling. That is an enormous R&D bill and it is exactly why margin is compressing. In this same release Amgen DISCONTINUED future development of AMG 513, its other obesity asset - there is no back-up. The Phase 2 data everyone extrapolates from showed up to about 20% weight loss at 52 weeks, at the low end of expectations with tolerability-driven discontinuations. Our base case assigns MariTide essentially nothing. - WHY WE DIFFER FROM WALL STREET - AND AGREE WITH ITS ARITHMETIC: 38 analysts cover Amgen (22 buy, 13 hold, 3 sell) and the consensus rating is Buy, with an average twelve-month target of $365.08 in a range of $303 to $427. Tuesday's close was $390.02 - so the Street's own average target sits 6% BELOW the price it rates a Buy. Our fair value is $356, theirs $365; those are the same answer. We simply call a stock 9% above fair value a HOLD, and we are modestly more CAUTIOUS because a flat second-half guide after a big beat is the more important sentence in this release. SOURCING: every figure is read off the 8-K EX-99.1 filed 2026-08-04, accession 0000318154-26-000124, grepped for 'Amgen' and 'June 30, 2026' before any number was taken; prior-guidance comparisons come from the Q1 2026 (0000318154-26-000054) and FY2025 (0000318154-26-000003) releases. Share count is off the filing (544M diluted), not FMP. What to watch: Bullish (what would change our mind fastest): a MARITIME-1 or MARITIME-2 readout showing competitive weight loss on genuinely monthly or quarterly dosing - that alone makes this model far too conservative. Also constructive: a single quarter where non-GAAP operating margin stops falling. Bearish: another leg down in Prolia and XGEVA without the growth drivers accelerating. Level: we would buy under $330, roughly 15% below our fair value, where the dividend yield reaches about 3.1%. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.